-Kriesche were employees of Bristol-Myers Squibb at the time that these analyses were undertaken.
≥18 years. 1 Belatacept was investigated in 2 randomized phase III studies: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) and BENEFITExtended Criteria Donors (BENEFIT-EXT). In these studies, patients
were de novo recipients of a living or standard criteria deceased donor kidney (BENEFIT) or an extended criteria donor kidney (BENEFIT-EXT) and randomized to receive up to 7 years of treatment with belatacept more-intense (MI)-based, belatacept lessintense (LI)-based, or cyclosporine-based immunosuppression. 2, 3 In an intent-to-treat analysis of BENEFIT undertaken at 7 years posttransplant, belatacept-based immunosuppression was associated with a 43% reduction in the risk of death or graft loss relative to cyclosporine-based immunosuppression (belatacept more HR 0.57, 95% CI 0.35-0.94, P = .02). 4 The risk of death or graft loss in belatacept-treated and cyclosporine-treated patients enrolled in BENEFIT-EXT was similar (belatacept MI vs cyclosporine: HR 0.92, 95% CI 0.63-1.34, P = .65; belatacept LI vs cyclosporine: HR 0.93, 95% CI 0.63-1.36, P = .70). 5 Estimated GFR was significantly higher in belatacept-treated vs cyclosporine-treated patients over 7 years of follow-up in both studies. 4, 5 No new safety signals emerged with longer duration of exposure to belatacept. 4, 5 In kidney-transplant recipients, the presence of donor-specific antibodies (DSAs) is associated with an increased risk of antibodymediated rejection and graft failure. 6 Approximately 11% of kidneytransplant recipients develop de novo DSAs within the first year after transplantation; this proportion increases to 20% by 5 years posttransplant. 7 The risk of antibody-mediated rejection and graft loss increases with higher mean fluorescence intensity (MFI), a semiquantitative measure of the number of DSAs circulating in patient sera. 8 On-treatment analyses of data from BENEFIT and BENEFIT-EXT showed the Kaplan-Meier cumulative event rates for de novo DSA development at 7 years posttransplant to be significantly lower with belatacept-based vs cyclosporine-based immunosuppression. 4, 5 In this updated analysis, MFI was also quantified in the subsets of patients from BENEFIT and BENEFIT-EXT who developed de novo DSAs.
| ME THODS

| Study design
BENEFIT (NCT00256750) and BENEFIT-EXT (NCT00114777) were 3-year, international, partially blinded, active-controlled, parallelgroup, randomized phase III studies. 4, 5 Patients in BENEFIT were transplanted with a living or standard criterion deceased-donor kidney. Patients in BENEFIT-EXT were transplanted with an extended criteria donor kidney, which was defined as those meeting United Network for Organ Sharing (UNOS) expanded donor criteria, those with an anticipated cold ischemia time ≥24 hours, or those donated after circulatory death. All patients in BENEFIT and BENEFIT-EXT were initially randomized (1:1:1) to receive belatacept MI-based, belatacept LI-based, or cyclosporine-based immunosuppression for 3 years. Following a protocol amendment, patients were allowed to continue the study treatment to which they had been randomized beyond 3 years, if approved by the treating physician and if the patient provided additional written informed consent. 9, 10 In addition to randomized treatment, all study participants received basiliximab induction, mycophenolate mofetil, and corticosteroids.
BENEFIT and BENEFIT-EXT were conducted in accordance with
Good Clinical Practice guidelines and the principles outlined in the Declaration of Helsinki. The institutional review boards/ethics committees at participating centers approved the study protocols. All patients provided written informed consent.
| Assessments
The presence of HLA antibodies was assessed in all randomized, transplanted patients at baseline, at months 6, 12, 24, 36, 48, 60, and 84, and at the time of any clinically suspected episodes of acute rejection. Antibody screening was performed centrally at Emory University using solid-phase flow cytometry screening were scored as negative. Sera were not pretreated or diluted prior to single-antigen bead testing. To minimize variation due to lot/ technician differences, all samples-irrespective of the time at which they were drawn-were tested and analyzed at the same time. Single-antigen bead testing was performed using a modified technique employing a biotin-conjugated secondary antibody followed by phycoerythrin-conjugated streptavidin. An MFI value of 2000 in this assay corresponds to a slightly lower MFI value than in the non-modified assay. Details on our modified technique are described. 
| Statistics
Analyses were performed on the intent-to-treat population. The absolute proportion of patients who developed de novo DSAs by year 7 (month 84) was calculated for each study. The cumulative incidence of de novo DSAs was analyzed separately for BENEFIT and BENEFIT-EXT and summarized using Kaplan-Meier curves and event rates. HRs and 95% CIs at month 84 were calculated via Cox regression. MFI in the subset of patients from each study who developed de novo DSAs was summarized using descriptive statistics. (Table 1) . Among cyclosporine-treated patients, 13 developed de novo DSAs with class I HLA specificity, 4 with class II HLA specificity, and 3 with both class I and class II HLA specificity. The HLA loci against which de novo DSAs developed are summarized in Table 1 .
| RE SULTS
| BENEFIT
The cumulative event rates of de novo DSAs at month 84 for belata- belatacept MI with cyclosporine was 0.31 (95% CI 0.13-0.74, P = .0078), and the HR for the comparison of belatacept LI with cyclosporine was 0.09 (95% CI 0.02-0.37, P < .001) ( Figure 2B 
| D ISCUSS I ON
The outcomes from this on-treatment analysis of de novo DSA development in the phase III BENEFIT and BENEFIT-EXT studies show that belatacept-based immunosuppression is associated with a significantly lower incidence of de novo DSA development relative to cyclosporine-based immunosuppression over 7 years DSAs, 63.6% (7/11) were HLA-DQ mismatched, but none had a HLA-DR mismatch. These data suggest an intriguing biological relationship between class II HLA-DQ mismatching and de novo DSA production that will need to be addressed in subsequent studies.
Due to the post hoc nature of these analyses and small sizes, these results should be interpreted with caution. In addition to these limitations, the inability to detect DSAs immediately prior to transplant does not prove that all DSAs measured posttransplant were de novo; pretransplant/preexisting DSAs could have been present at levels below the sensitivity of the assays used or have resulted from a memory response. Despite these caveats, these preliminary results suggest that belatacept-based immunosuppression prevents de novo DSA development more effectively than cyclosporine-based immunosuppression.
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